<DOC>
	<DOCNO>NCT01233128</DOCNO>
	<brief_summary>This study investigate whether association LOC387715/HTRA1 vascular endothelial growth factor polymorphism response treatment intravitreal ranibizumab injection patient polypoidal choroidal vasculopathy .</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor ( VEGF ) &amp; LOC387715/HTRA1 Polymorphism Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>This retrospective comparative case series comprise 70 patient treat polypoidal choroidal vasculopathy intravitreal ranibizumab injection 112 control subject . Patients genotyped LOC387715 ( rs10490924 ) , HTRA1 gene ( rs11200638 ) , VEGF ( rs3025039 rs833069 ) polymorphism use Real-Time polymerase chain reaction .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>patient older 60 year age onset polyplike terminal aneurysmal dilation without branch vascular network ICGA subretinal reddishorange protrusion correspond polyplike lesion patient intravitreal injection 0.5 mg ranibizumab monthly 3 month patient retinal choroidal disease include pathologic myopia , angioid streak , idiopathic choroidal neovascularization ( CNV ) , presume ocular histoplasmosis , secondary CNV patient refuse genotypic analysis</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>